Macronutrient Distribution and Plasma Metabolites to Model Meals Composition
Study Details
Study Description
Brief Summary
Continuous glucose monitors (CGMs) measure plasma glucose concentration continually and thus they are a key tool in the management of diabetes, including type 2 diabetes (T2D). A key factor in diabetes management is a reduction of dietary carbohydrates (CHO) and/or exchanging high glycemic index (GI) CHO with low GI CHO. However, the protein and fat content of the meal can have a significant impact on the glucose readings obtained from a CGM as there is no enough data available on their sensitivity during meals.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The study involves 1 screening visit of approximately 1 hour and 9 study days of approximately 8 hours. Subjects will be asked to arrive in the fasted state on all study days. Fasting prior to screening is not required. On the screening day, body weight, height, and body composition by Dual-energy X-ray absorptiometry (DXA) will be measured. In addition, habitual dietary intake, physical activity level (PASE), and quality of life (SGRQ-C) will be assessed.
To test the relation between plasma amino acid, triglycerides, and glucose concentration measured by standard methods (such as finger stick) and continuous wearable devices, a premarket FDA-approved continuous glucose monitor (CGM) from Abbott (FreeStyle Libre Pro) that monitors glucose concentrations every 15 min is used. The single-use sensors are placed on the upper arm and contain a very tiny 5 mm filament (<0.4 mm diameter) that is introduced into the skin when the sensor is placed. On the first study day, the CGM will be placed to monitor glucose concentrations until the last study day. At least every 14 days, sensors will be replaced by new ones. On each study day, body weight and height will be measured and the glucose concentration data will be downloaded from the sensor onto the reader device. A catheter will be inserted in a peripheral vein of the lower arm or hand to enable blood sampling. The arm will be put in a hot box to allow collecting arterialized venous blood samples. After taking a baseline blood sample, the predefined meal will be consumed within 10 min. Small arterialized venous blood samples (5 ml) will subsequently be drawn at times: 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420, and 480 minutes (13 blood samples, total blood approx 65 ml). Samples will be collected in predefined tubes, plasma/serum separated, aliquoted, and stored at -80 deg. Celsius for later assays and/or send to a local accredited laboratory for the concentrations of amino acids and other parameters (including fatty acids, glucose, insulin).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Non-diabetic older adults Non-diabetic older adults |
Combination Product: Predefined meal
Nine predefined meals are administered in a randomized fashion, one meal per one study day, 2-3 study days per week. Meals have a form of drinks with different compositions of protein, carbohydrates and fat in relation to the US diet
|
Outcome Measures
Primary Outcome Measures
- Prediction models of postprandial plasma amino acid patterns in relation to the macronutrient content of predefined meals as assessed by plasma concentrations of amino acids, glucose, and/or triglycerides [9 study visits: one meal per one study day, 2-3 meals per week, 8-hour blood blood sample collection after a meal intake. Study completion: 4-5 weeks.]
Participants consume 9 predefined meals in the fasted state with macronutrient composition reflecting common meals in the US diet. One meal is consumed during one study visit with a total of 9 visits. A baseline sample is collected followed by an intake of one meal during one study visit. Blood samples (in the 15-and 30-minutes interval) are collected for 8 hours after a meal intake. Collected plasma will be used for amino acid analysis. Statistical models will be used to predict plasma amino acids from patterns of amino acids, glucose, and/or triglycerides in the consumed meals.
Secondary Outcome Measures
- Discordance of glucose measurement after an intake of the predefined meal as measured by a fingerstick, continuous glucose monitor, and certified laboratory [9 study visits: one meal per one study day, 2-3 meals per week, 8-hour blood blood sample collection after a meal intake. Study completion: 4-5 weeks.]
A continuous glucose monitor is placed during the first study visit. Participants consume 9 predefined meals in the fasted state with macronutrient composition reflecting common meals in the US diet. One meal is consumed during one study visit. A baseline sample is collected followed by an intake of one meal during one study visit. Blood samples (in the 15-and 30-minutes interval) for glucose measurements are taken and plasma samples are collected. Plasma glucose is measured by a glucose monitor and outsourced to the certified laboratory. Information from continuous glucose monitor is collected at the end of each study day.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Ability to walk, sit down and stand up independently
-
Ability to lie in a supine or slightly elevated position for 8.5 hours
-
BMI between 25 and 35 kg/m2
-
Willingness and ability to comply with the protocol
Exclusion Criteria:
-
Established diagnosis of malignancy
-
Established diagnosis of Insulin-Dependent Diabetes Mellitus
-
History of untreated metabolic diseases including hepatic or renal disorder
-
Presence of acute illness or metabolically unstable chronic illness
-
Recent myocardial infarction (less than 1 year)
-
Any other condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
-
Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Texas A&M University | College Station | Texas | United States | 77843 |
Sponsors and Collaborators
- Texas A&M University
- U.S. National Science Foundation
Investigators
- Principal Investigator: Nicolaas EP Deutz, MD, PhD, Texas A&M University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2017-0886